Cerus (CERS) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Cerus Corporation Reports Fourth Quarter and Year End 2016 Results
March 7, 2017 4:01 PM ESTCONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (NASDAQ: CERS) today announced financial results for the fourth quarter and year ended December 31, 2016.
Recent developments include:
The U.S. Food and Drug Administration's Center for Biologics Evaluation and Research (CBER) intends to release final guidance on bacterial contamination of platelets this year, according to its recently published Guidance Document Agenda for 2017. Cerus estimates that at least 7 U.S. blood center customers, including the American Red Cross, have submitted biologics license applications to the FDA to request allowance for the interstate transport... More